San Antonio Breast Cancer Symposium Presentation Session Time - - PDF document

San Antonio Breast Cancer Symposium

Tuesday, December 10, 2019

Presentation

Defining a cancer dependency map William C. Hahn, MD, PhD Dana-Farber Cancer Institute Design and analysis of window and neoadjuvant trials Meredith Regan, ScD Dana-Farber Cancer Institute Neoadjuvant therapy for hormone receptor positive breast cancer: Advances and challenges Otto Metzger, MD Dana-Farber Cancer Institute Surgical considerations AFTER preoperative therapy for hormone receptor positive breast cancer Tari Ann King, MD Dana-Farber Cancer Institute Progression of disease and end of life: How to break bad news Eric P. Winer, MD Dana-Farber Cancer Institute Future directions in endocrine therapy for advanced HER+/HER2- breast cancer Erica L. Mayer, MD, MPH Dana-Farber Cancer Institute

Session

Workshop: Molecular Biology in Breast Oncology - Moderator: Carlos L. Arteaga, MD Workshop: Developing Novel Therapeutics in the Metastatic Setting - Moderator: Virginia G. Kaklamani, MD UT Health San Antonio Workshop: Multidisciplinary Approaches to Optimizing Surgical Therapy for Hormone Receptor Positive Breast Cancer – Moderator: Armando Giuliano, MD Cedars-Sinai Medical Center Workshop: Multidisciplinary Approaches to Optimizing Surgical Therapy for Hormone Receptor Positive Breast Cancer – Moderator: Armando Giuliano, MD Cedars-Sinai Medical Center Workshop: Conversations on Tough Topics Surrounding Cancer Care – Moderator: Susan Rafte Community Advocate, Baylor College of Medicine Breast Center Houston, TX Workshop: Endocrine Therapy in 2020 Moderator: Mothaffar Rimawi, MD Baylor College of Medicine

Time

11:45 am - 1:45 pm 11:45 am - 1:45 pm 3:45 pm - 5:15 pm 3:45 pm - 5:15 pm 3:45 pm - 5:15 pm 3:45 pm - 5:15 pm

Location

Hemisfair Ballroom - 3rd Level Stars at Night Ballroom - 3rd Level Stars at Night Ballroom 1 - 3rd Level Stars at Night Ballroom 1 - 3rd Level Stars at Night Ballroom 3&4 - 3rd Level Hemisfair Ballroom - 3rd Level

San Antonio Breast Cancer Symposium

Wednesday, December 11, 2019

Presentation

Tucatinib vs placebo, both combined with capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases (HER2CLIMB), Eric Winer, MD (senior author) [Fam-] trastuzumab deruxtecan (T-DXd; DS- 8201a) in subjects with HER2-positive meta- static breast cancer previously treated with T-DM1: A phase 2, multicenter, open-label study (DESTINY-Breast01), Ian Krop, MD, PhD Tbcrc 033: A randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzum- ab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT) Sara Tolaney, MD, MPH Introduction Discussion Eric Winer, MD Dana-Farber Cancer Institute Systemic therapy for breast cancer brain metastases Nancy U. Lin, MD Dana-Farber Cancer Institute Acquired activating mutations in RTKs con- fer endocrine resistance in ER+ metastatic breast cancer through ER-reprogramming, MAPK signaling, and an induced stem-like cell state Nikhil Wagle, MD, Dana-Farber Cancer Institute, senior author Improvements in long-term outcome for women with estrogen receptor positive (ER+) early stage breast cancer treated with 5 years of endocrine therapy: Analyses of 82,598 women in the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) database Richard D. Gelber, PhD

Session

GS 1-01 GS1-03 GS1-05 CAREER DEVELOPMENT FORUM

• Room 304

CLINICAL SCIENCE FORUM - Frontiers in HER2 Positive Breast Cancer Moderator: Sibylle Loibl, MD German Breast Group GS2-02 GS2-04

Time

8:45 am 9:15 am 9:45 am 12:00 - 12:05 pm 1:00 pm - 2:00 pm 3:30 pm 4:00 pm

Location

Hall 3 Hall 3 Hall 3 Room 304 Stars at Night Ballroom 3&4 - 3rd Level Hall 3 Hall 3

San Antonio Breast Cancer Symposium

Thursday, December 12, 2019

Presentation

Targeting HER2 and DNA Repair Chair: Ian Krop, MD, PhD Dana-Farber Cancer Institute Multiplatform analysis of matched primary and metastatic breast tumors from the AURORA US Network Tari King, MD Dana-Farber Cancer Institute Essential Genes and Cistromes in Breast Cancer Myles Brown, MD Dana-Farber Cancer Institute Panel Q&A: Getting the Most from Your Training Eric Winer, MD Panelist Tari A. King, MD Dana-Farber Cancer Center Panelist Immunotherapy in breast cancer: enhancing response to checkpoint blockade Elizabeth A. Mittendorf, MD, PhD Dana-Farber Cancer Institute Brigham and Women’s Cancer Center

Session

SPOTLIGHT SESSION 4: GS3-07 AACR DISTINGUISHED LECTURESHIP IN BREAST CANCER RESEARCH CAREER DEVELOPMENT FORUM

• Room 304

CASE DISCUSSION 1 – Stars at Night Ballroom 1&2 - 3rd Level MINI-SYMPOSIUM 1

Time

7:00 am – 9am 11:15 am 11:30 am - 12:00 pm 12:00 pm - 1:00 pm 1:00 pm - 2:00 pm 2:15 pm - 3:15 pm

Location

Stars at Night Ballroom 1&2 - 3rd Level Hall 3 Hall 3 Room 304 Stars at Night Ballroom 1&2 - 3rd Level Hall 3

San Antonio Breast Cancer Symposium

Friday, December 13, 2019

Presentation

Cost and value Michael Hasset, MD, MPH Discussant Dana-Farber Cancer Institute Targeting the cell cycle - Beyond CDK4/6 inhibition Rinath Jeselsohn, MD Dana-Farber Cancer Institute A joint atlas of single-cell and bulk RNA-seq in metastatic breast cancer allows inference of

• ncogenic and drug-resistant transcriptional

programs in malignant cells and the tumor microenvironment Nikhil Wagle, MD, Dana-Farber Cancer Institute, senior author

Session

SPOTLIGHT SESSION 10: Tox- icity, Tolerability & Cost - Chair: Katherine Reeder-Hayes, MD University of North Carolina MINI-SYMPOSIUM 2 - GS6-04

Time

7:00 am - 9:00 am 2:15 pm - 3:15 pm 4:00 pm

Location

Stars at Night Ballroom 3&4 - 3rd Level Hall 3 Hall 3